|
|
|
|
Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells.
Wu S, Vossius S, Rahmouni S, Miletic AV, Vang T, Vazquez-Rodriguez J, Cerignoli F, Arimura Y, Williams S, Hayes T, Moutschen M, Vasile S, Pellecchia M, Mustelin T, Tautz L
J Med Chem. 2009 Nov 12;52(21):6716-23
A TR3/Nur77 peptide-based high-throughput fluorescence polarization screen for small molecule Bcl-B inhibitors.
Yip KW, Godoi PH, Zhai D, Garcia X, Cellitti JF, Cuddy M, Gerlic M, Chen Y, Satterthwait A, Vasile S, Sergienko E, Reed JC
J Biomol Screen. 2008 Aug;13(7):665-73
Preclinical studies of celastrol and acetyl isogambogic acid in melanoma.
Abbas S, Bhoumik A, Dahl R, Vasile S, Krajewski S, Cosford ND, Ronai ZA
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6769-78
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D
Mol Cancer Ther. 2006 Jul;5(7):1774-82
The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase alpha is mediated by hydrogen peroxide.
Bova MP, Mattson MN, Vasile S, Tam D, Holsinger L, Bremer M, Hui T, McMahon G, Rice A, Fukuto JM
Arch Biochem Biophys. 2004 Sep 1;429(1):30-41
View All Publications
Steve Vasile's Research Focus
Steve joined the Sanford-Burnham Institute in October 2003 as Director of High Throughput Screening to establish screening technologies at the institute. He was instrumental in Sanford-Burnham becoming an NIH comprehensive screening center both in the pilot, as well as production phases of the NIH’s Molecular Libraries Roadmap Initiative.
About Steve Vasile
Experience
Prior to joining Sanford-Burnham he was at Sugen Inc. (a wholly owned subsidiary of Pharmacia). Sugen, a leading signal transduction company, elucidated the human kinome. Dr. Vasile joined Sugen in 1995, where he eventually became co-leader of Discovery Technology. The Discovery Technology department performed assay development, as well as high throughput screening primarily on kinase and phosphatase targets. His team was the first to determine the kinase inhibition properties of Sutent (aka sunitinib malate). This multi-billion dollar drug is marketed by Pfizer for the treatment of renal cancer as well as Gleevec resistant GIST. Dr. Vasile has over 17 years of experience in assay development, high throughput screening and lab automation. He received his Ph.D. in Biochemistry in 1993 from Roswell Park Cancer Institute/State University of New York at Buffalo, where his doctoral thesis focused on human leukemia antigens. His post-doctoral work was performed at Harbor Branch Oceanographic Institute where he developed and ran a number of phosphatase screens through Harbor Branch’s extensive library of deep water marine natural product extracts. During his tenure at Harbor Branch he was able to travel multiple times 3000 feet into the abyss aboard their research submersibles.
|
|
|
|
|
|